Those who have the sleep disorder idiopathic hypersomnia finally have relief. But it comes in the form of a medicine with tight regulations and safety concerns. On Thursday, Jazz Pharmaceuticals ...
Jazz Pharmaceuticals plc JAZZ announced that the U.S. Drug Enforcement Agency (“DEA”) has designated its recently approved sleep drug, Sunosi (solriamfetol), as a Schedule IV medicine. The designation ...
Jazz Pharmaceuticals plc JAZZ announced that the European Commission approved its new sleep drug, Sunosi (solriamfetol). The drug will be available in Europe as a treatment to improve wakefulness and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results